Cinzia Crivellaro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3662373/publications.pdf Version: 2024-02-01

33 papers	1,134 citations	³⁹⁴⁴²¹ 19 h-index	414414 32 g-index
33	33	33	1497
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 13-26.	6.4	147
2	Impact of Indocyanine Green for Sentinel Lymph Node Mapping in Early Stage Endometrial and Cervical Cancer: Comparison with Conventional Radiotracer 99mTc and/or Blue Dye. Annals of Surgical Oncology, 2016, 23, 2183-2191.	1.5	91
3	Preoperative staging of cervical cancer: Is 18-FDG-PET/CT really effective in patients with early stage disease?. Gynecologic Oncology, 2011, 123, 236-240.	1.4	74
4	18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer. Gynecologic Oncology, 2012, 127, 131-135.	1.4	74
5	Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: A prospective study. Gynecologic Oncology, 2013, 131, 395-399.	1.4	66
6	From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach. Annals of Surgical Oncology, 2016, 23, 2959-2965.	1.5	61
7	Staging of High-Risk Endometrial Cancer With PET/CT and Sentinel Lymph Node Mapping. Clinical Nuclear Medicine, 2015, 40, 780-785.	1.3	60
8	Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: The role of 18F-FDG PET/CT. Gynecologic Oncology, 2013, 130, 306-311.	1.4	59
9	Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer. Gynecologic Oncology, 2013, 131, 689-693.	1.4	54
10	Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiotherapy and Oncology, 2010, 96, 347-350.	0.6	49
11	Predictive value of 18F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 404-413.	6.4	47
12	Radiomics of the primary tumour as a tool to improve 18F-FDC-PET sensitivity in detecting nodal metastases in endometrial cancer. EJNMMI Research, 2018, 8, 86.	2.5	43
13	Indocyanine Green versus Radiotracer with or without Blue Dye for Sentinel Lymph Node Mapping in Stage >IB1 Cervical Cancer (>2Âcm). Journal of Minimally Invasive Gynecology, 2017, 24, 954-959.	0.6	39
14	Comparative analysis of iterative reconstruction algorithms with resolution recovery for cardiac SPECT studies. A multi-center phantom study. Journal of Nuclear Cardiology, 2014, 21, 135-148.	2.1	35
15	Sentinel-node mapping in endometrial cancer patients: comparing SPECT/CT, gamma-probe and dye. Annals of Nuclear Medicine, 2017, 31, 93-99.	2.2	28
16	Quality of Care for Cervical and Endometrial Cancer Patients: The Impact of Different Techniques of Sentinel Lymph Node Mapping on Patient Satisfaction. Annals of Surgical Oncology, 2016, 23, 2975-2981.	1.5	26
17	18F-FDG PET/CT in preoperative staging of vulvar cancer patients. Medicine (United States), 2017, 96, e7943.	1.0	24
18	Real-Time Fluorescent Sentinel Lymph Node Mapping with Indocyanine Green in Women with Previous Conization Undergoing Laparoscopic Surgery for Early Invasive Cervical Cancer: Comparison with Radiotracer ± Blue Dye. Journal of Minimally Invasive Gynecology, 2018, 25, 455-460.	0.6	22

CINZIA CRIVELLARO

#	Article	IF	CITATIONS
19	Added diagnostic value of respiratory-gated 4D 18F–FDG PET/CT in the detection of liver lesions: a multicenter study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 102-109.	6.4	22
20	Combining positron emission tomography/computed tomography, radiomics, and sentinel lymph node mapping for nodal staging of endometrial cancer patients. International Journal of Gynecological Cancer, 2020, 30, 378-382.	2.5	20
21	Respiratory Motion Management in PET/CT: Applications and Clinical Usefulness. Current Radiopharmaceuticals, 2017, 10, 85-92.	0.8	19
22	The "digital biopsy―in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3401-3411.	6.4	19
23	Intrathoracic splenosis: evaluation by 99mTc-labelled heat-denatured erythrocyte SPECT/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 412-412.	6.4	10
24	Motion Management in PET/CT: Technological Solutions. Current Radiopharmaceuticals, 2018, 11, 79-85.	0.8	9
25	Sentinel node biopsy in endometrial cancer: an update. Clinical and Translational Imaging, 2018, 6, 91-100.	2.1	6
26	Temporal lobe dysfunction in late-onset epilepsy of unknown origin. Epilepsy and Behavior, 2021, 117, 107839.	1.7	6
27	The heterogeneity of lung perfusion patterns in SPECT/CT during COVID-19: not only embolism. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3020-3021.	6.4	6
28	Role of PET/CT in the clinical management of locally advanced pancreatic cancer. Tumori, 2012, 98, 643-51.	1.1	6
29	Focal bone lesions in hiv-positive patient treated with tenofovir. BMC Infectious Diseases, 2014, 14, 131.	2.9	4
30	Treatment response assessment in [18F]FDG-PET/CT oncology scans: Impact of count statistics variation and reconstruction protocol. Physica Medica, 2019, 57, 177-182.	0.7	4
31	Respiratory Gating and the Performance of PET/CT in Pulmonary Lesions. Current Radiopharmaceuticals, 2020, 13, 218-227.	0.8	3
32	Clinical Application of a High Sensitivity BGO PET/CT Scanner: Effects of Acquisition Protocols and Reconstruction Parameters on Lesions Quantification. Current Radiopharmaceuticals, 2022, 15, 218-227.	0.8	1
33	Cervical injection for sentinel lymph nodes detection in endometrial cancers is controversial: response to comments. Clinical and Translational Imaging, 2018, 6, 251-252.	2.1	Ο